High-mobility group box 1 is involved in the development of benign prostatic hyperplasia with chronic prostatic inflammation.

about

High-mobility group box 1 is involved in the development of benign prostatic hyperplasia with chronic prostatic inflammation.

Item

http://www.wikidata.org/entity/Q40768004

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

High-mobility group box 1 is i ...... hronic prostatic inflammation.

@en

type

Item

label

High-mobility group box 1 is i ...... hronic prostatic inflammation.

@en

prefLabel

High-mobility group box 1 is i ...... hronic prostatic inflammation.

@en

P1476

High-mobility group box 1 is i ...... hronic prostatic inflammation.

@en

P2093

Jingjing Xu

http://www.w3.org/2001/XMLSchema#string

Jinjian Yang

http://www.w3.org/2001/XMLSchema#string

Rui Xue

http://www.w3.org/2001/XMLSchema#string

Shengli Ma

http://www.w3.org/2001/XMLSchema#string

Zhankui Jia

http://www.w3.org/2001/XMLSchema#string

P2860

Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways

Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products

Release of chromatin protein HMGB1 by necrotic cells triggers inflammation

HMG-1 as a late mediator of endotoxin lethality in mice

Revised nomenclature for high mobility group (HMG) chromosomal proteins

RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages

The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells

The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.

High prevalence of benign prostatic hypertrophy in the community.

American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited.

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/21681805.2015.1059357

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26143661

http://www.w3.org/2001/XMLSchema#string